Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 13/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.56 |
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274325 | 0.90 | HDAC2 (0.61) | HDAC2HDAC3KCNH2HDAC1ACLY | |
| SCHEMBL2272718 | 0.87 | HDAC2 (0.58) | HDAC2HDAC3KCNH2HDAC1 | |
| SCHEMBL2276392 | 0.86 | DGAT1 (0.50) | HDAC2HDAC3KCNH2HDAC1TRPV1 | |
| SCHEMBL2274078 | 0.85 | SMN1; SMN2 (0.49) | HDAC2HDAC3KCNH2HDAC1TRPV1 | |
| SCHEMBL2269782 | 0.84 | ACLY (0.56) | HDAC2HDAC3KCNH2HDAC1ACLY | |
| SCHEMBL1317654 | 0.80 | ACLY (0.62) | HDAC2HDAC3KCNH2HDAC1ACLY | |
| SCHEMBL2573087 | 0.79 | ACLY (0.67) | HDAC2HDAC3HDAC1ACLYDHODH | |
| SCHEMBL2276276 | 0.79 | ALDH1A1 (0.54) | HDAC1ACLYDHODH | |
| SCHEMBL27696834 | 0.78 | MCHR1 (0.60) | HDAC1TRPV1 | |
| SCHEMBL2270222 | 0.78 | DHODH (0.77) | HDAC2HDAC3HDAC1ACLYDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | HDAC2 276/4885HDAC3 87/4885KCNH2 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.